Abstract
Background: Exercise interventions often aim to affect abdominal obesity and glucose tolerance, two significant risk factors for type 2 diabetes. Because of limited financial and clinical resources in community and university-based environments, intervention effects are often measured with interviews or questionnaires and correlated with weight loss or body fat indicated by body bioimpedence analysis (BIA). However, self-reported assessments are subject to high levels of bias and low levels of reliability. Because obesity and body fat are correlated with diabetes at different levels in various ethnic groups, data reflecting changes in weight or fat do not necessarily indicate changes in diabetes risk. To determine how exercise interventions affect diabetes risk in community and university-based settings, improved evaluation methods are warranted. Methods: We compared a noninvasive, objective measurement technique-regional BIA-with whole-body BIA for its ability to assess abdominal obesity and predict glucose tolerance in 39 women. To determine regional BIA's utility in predicting glucose, we tested the association between the regional BIA method and blood glucose levels. Results: Regional BIA estimates of abdominal fat area were significantly correlated (r=0.554, P<0.003) with fasting glucose. When waist circumference and family history of diabetes were added to abdominal fat in multiple regression models, the association with glucose increased further (r=0.701, P<0.001). Conclusions: Regional BIA estimates of abdominal fat may predict fasting glucose better than whole-body BIA as well as provide an objective assessment of changes in diabetes risk achieved through physical activity interventions in community settings.
| Original language | English |
|---|---|
| Pages (from-to) | 557-561 |
| Number of pages | 5 |
| Journal | Diabetes Technology and Therapeutics |
| Volume | 13 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2011 |
Fingerprint
ASJC Scopus subject areas
- Endocrinology
- Endocrinology, Diabetes and Metabolism
- Medical Laboratory Technology
Cite this
Developing an objective evaluation method to estimate diabetes risk in community-based settings. / Kenya, Sonjia; He, Qing; Fullilove, Robert; Kotler, Donald P.
In: Diabetes Technology and Therapeutics, Vol. 13, No. 5, 01.05.2011, p. 557-561.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Developing an objective evaluation method to estimate diabetes risk in community-based settings
AU - Kenya, Sonjia
AU - He, Qing
AU - Fullilove, Robert
AU - Kotler, Donald P.
PY - 2011/5/1
Y1 - 2011/5/1
N2 - Background: Exercise interventions often aim to affect abdominal obesity and glucose tolerance, two significant risk factors for type 2 diabetes. Because of limited financial and clinical resources in community and university-based environments, intervention effects are often measured with interviews or questionnaires and correlated with weight loss or body fat indicated by body bioimpedence analysis (BIA). However, self-reported assessments are subject to high levels of bias and low levels of reliability. Because obesity and body fat are correlated with diabetes at different levels in various ethnic groups, data reflecting changes in weight or fat do not necessarily indicate changes in diabetes risk. To determine how exercise interventions affect diabetes risk in community and university-based settings, improved evaluation methods are warranted. Methods: We compared a noninvasive, objective measurement technique-regional BIA-with whole-body BIA for its ability to assess abdominal obesity and predict glucose tolerance in 39 women. To determine regional BIA's utility in predicting glucose, we tested the association between the regional BIA method and blood glucose levels. Results: Regional BIA estimates of abdominal fat area were significantly correlated (r=0.554, P<0.003) with fasting glucose. When waist circumference and family history of diabetes were added to abdominal fat in multiple regression models, the association with glucose increased further (r=0.701, P<0.001). Conclusions: Regional BIA estimates of abdominal fat may predict fasting glucose better than whole-body BIA as well as provide an objective assessment of changes in diabetes risk achieved through physical activity interventions in community settings.
AB - Background: Exercise interventions often aim to affect abdominal obesity and glucose tolerance, two significant risk factors for type 2 diabetes. Because of limited financial and clinical resources in community and university-based environments, intervention effects are often measured with interviews or questionnaires and correlated with weight loss or body fat indicated by body bioimpedence analysis (BIA). However, self-reported assessments are subject to high levels of bias and low levels of reliability. Because obesity and body fat are correlated with diabetes at different levels in various ethnic groups, data reflecting changes in weight or fat do not necessarily indicate changes in diabetes risk. To determine how exercise interventions affect diabetes risk in community and university-based settings, improved evaluation methods are warranted. Methods: We compared a noninvasive, objective measurement technique-regional BIA-with whole-body BIA for its ability to assess abdominal obesity and predict glucose tolerance in 39 women. To determine regional BIA's utility in predicting glucose, we tested the association between the regional BIA method and blood glucose levels. Results: Regional BIA estimates of abdominal fat area were significantly correlated (r=0.554, P<0.003) with fasting glucose. When waist circumference and family history of diabetes were added to abdominal fat in multiple regression models, the association with glucose increased further (r=0.701, P<0.001). Conclusions: Regional BIA estimates of abdominal fat may predict fasting glucose better than whole-body BIA as well as provide an objective assessment of changes in diabetes risk achieved through physical activity interventions in community settings.
UR - http://www.scopus.com/inward/record.url?scp=79955556027&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955556027&partnerID=8YFLogxK
U2 - 10.1089/dia.2010.0195
DO - 10.1089/dia.2010.0195
M3 - Article
C2 - 21406009
AN - SCOPUS:79955556027
VL - 13
SP - 557
EP - 561
JO - Diabetes Technology and Therapeutics
JF - Diabetes Technology and Therapeutics
SN - 1520-9156
IS - 5
ER -